Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET

Journal of Nuclear Medicine

Volumn 37, Issue 9, 1996, Pages 1438-1444

  Jones, D N ^a,b   McCowage, G B ^a   Sostman, H D ^a   Brizel, D M ^a   Layfield, L ^a   Charles, H C ^a   Dewhirst, M W ^a   Prescott, D M ^a   Friedman, H S ^a   Harrelson, J M ^a   Scully, S P ^a   Coleman, R E ^a  

^a DUKE UNIVERSITY   (United States)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

fluorine 18 fluoredeoxyglucose; PET; sarcoma; therapeutic monitoring

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; GADOLINIUM PENTETATE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERTHERMIC THERAPY; MALE; MUSCULOSKELETAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; TUMOR NECROSIS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; COMBINED MODALITY THERAPY; DEOXYGLUCOSE; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; MUSCLE NEOPLASMS; SARCOMA; SOFT TISSUE NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 10144250937     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Reiman RE, Rosen G, Gelbard AS, et al. Diagnostic demands in clinical and experimental oncology: application of substrates labeled with positron-emitting radionuclides. In: Current topics in tumor cell physiology and PET. New York: Springer-Verlag, 1984:73-85.
2. Kern KA, Brunetti A, Norton JA, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 1988;29:181-186.
3. 18F-FDG. J Comput Assist Tomogr 1990;14:960-962.
4. Adler LP, Blair HF, Makley JT, et al. Comparison of PET with CT, MRI and conventional scintigraphy in a benign and in a malignant soft tissue tumor. Orthopedics 1991;14:891-894.
5. Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991;32:1508-1512.
6. Griffeth LK, Dehdashti F, McGuire AH, et al. PET evaluation of soft tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. Radiology 1992;182:185-194.
7. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15.
8. Picci P, Rougraff BT, Bacci G, et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastalic Ewing's sarcoma of the extremities. J Clin Oncol 1993;11:1763-1769.
9. Fletcher BD. Response of osteosarcoma and Ewing sarcoma to chemotherapy: imaging evaluation. AJR 1991;157:825-833.
10. Sostman HD, Prescott DM, Dewhirst MW, et al. MR imaging and spectroscopy for prognostic evaluation in soft tissue sarcomas. Radiology 1994;190:269-275.
11. Royal HD. Clinical Applications of PET in cancer: the good, the bad and the ugly [Editorial]. J Nucl Med 1992;33:330-332.
12. 18F-fluorodeoxyglucose for the evaluation of therapeutic isolated regional limb perfusion in a patient with soft-tissue sarcoma. J Nucl Med 1994;35:90-92.
13. Lawrence JA, Babyn PS, Chan HSL, et al. Extremity osteosarcoma in childhood: prognostic value of radiologie imaging. Radiology 1993;189:43-47.
14. Redmond OM, Stack JP, O'Connor NG, et al. Phosphorus-31 MRS as an early prognostic indicator of patient response to chemotherapy. Magn Res Med 1992;25:30-44.
15. 31P MR spectroscopy. Radiology 1988;166:533-539.
16. Dewhirst MW, Sostman HD, Leopold KA, et al. Soft-tissue sarcomas: MR imaging and MR spectroscopy for prognosis and therapy monitoring. Radiology 1990;174:847-853.
17. Erlemann R, Sciuk J, Bosse A, et al. Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphy. Radiology 1990;175:791-796.
18. Fletcher BD, Hanna SL, Fairclough DC, Gronemeyer SA. Pediatric musculoskeletal tumors: use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy. Radiology 1992;184:243-248.
19. Hanna SL, Parham DM, Fairclough DL, Meyer WH, Le AH, Fletcher BD. Assessment of osteosarcoma response to preoperative chemotherapy using dynamic FLASH gadolinium DTPA-enhanced magnetic resonance mapping. Invest Radiol 1992;27:367-373.
20. Menendez LR, Fideler BM, Mirra J. Thallium-201 scanning for the evaluation of osteosarcoma and soft-tissue sarcoma. J Bone Joint Surg 1993;75:526-531.
21. Ramanna L, Waxman A, Binney G, Waxman S, Mirra J, Rosen G. Thallium-201 scintigraphy in bone sarcoma: comparison with gallium-67 and technetium-99m-MDP in the evaluation of chemotherapeutic response. J Nucl Med 1990;31:567-572.
22. Van Der Woude HJ, Bloem JL, Schipper J, et al. Changes in tumor permsion induced by chemotherapy in bone sarcomas: color Doppler flow imaging compared with contrast-enhanced MR imaging and three-phase bone scintigraphy. Radiology 1994;191:421-431.
23. Wahl RL, Zasadny K, Helvie M, Huchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101-2111.
24. Berlangieri SU, Brizel DM, Scher RL, et al. Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy. Head and Neck 1994;16:340-346.
25. Okazumi S, Isono K, Enomoto K, et al. Evaluation of liver rumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 1992;33:333-339.
26. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991;32:1485-1490.
27. Strauss LG, Tilgen W, Dimitrakopoulou A, et al. PET studies with fluorine-18-deoxyglucose in patients with metastatic melanoma prior and after therapy [Abstract]. J Nucl Med 1990;31:804.
28. Okada J, Yoshikawa K, Itami M, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992;33:325-329.
29. Ichiya Y, Kuwabara Y, Otsuka M, et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 1991;32:1655-1660.
30. Higashi K, Clavo A, Wahl R. Reply [Letter]. J Nucl Med 1993;34:2279-2280.
31. Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-1980.
32. Sanchez RB, Quinn SF, Walling A, et al. Musculoskeletal neoplasms after intraarterial chemotherapy: correlation of MR images with pathologic specimens. Radiology 1990;174:237-240.